Viveve Medical, Inc. (VIVE) News
Filter VIVE News Items
VIVE News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest VIVE News From Around the Web
Below are the latest news stories about VIVEVE MEDICAL INC that investors may wish to consider to help them evaluate VIVE as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayWe're starting off Tuesday with a look at the biggest pre-market stock movers that traders will want to keep an eye on today! |
Viveve Announces Completion of Pivotal US PURSUIT Trial for Female Stress Urinary Incontinence with Final 12-month Follow-up Visits ConcludedViveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and treatment of female stress urinary incontinence, today announced the completion of final 12-month post-treatment follow-up visits in its landmark U.S. PURSUIT clinical trial for the treatment of stress urinary incontinence (SUI) in women. A total of 415 patients were enrolled in the trial, and 342 patients completed 12-month follow-up visits. |
Viveve Announces Issuance of Second U.S. Method Patent for Treating Female Stress Urinary Incontinence/ Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of female stress urinary incontinence (SUI), today announced the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11511110 covering Viveve's treatment to address SUI in women. The issuance of the new patent strengthens the Company's intellectual property portfolio in advance of the planned completion of its U.S. |
Viveve Medical Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues LagViveve Medical ( NASDAQ:VIVE ) Third Quarter 2022 Results Key Financial Results Revenue: US$1.68m (up 4.2% from 3Q... |
Viveve Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateViveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of female stress urinary incontinence (SUI), today reported financial results for the quarter ended September 30, 2022, and will provide a corporate update on its scheduled conference call at 5:00 PM ET today. |
Viveve to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 10, 2022Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that it will report its third quarter 2022 financial results and provide a corporate update after the close of the U.S. financial markets on Thursday, November 10, 2022. |
Viveve Announces Notice of Allowance for Second U.S. Method Patent for Treating Female Stress Urinary Incontinence/ Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of female stress urinary incontinence (SUI), today announced the Company received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application 16/454,578 covering Viveve's unique dual-energy treatment to address SUI in women. |
Viveve Launches Rebranding Initiative to Reflect Focus on Treatment of Female Stress Urinary Incontinence in Anticipation of U.S. Pivotal PURSUIT Trial Readout/ Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of female stress urinary incontinence (SUI), today announced the launch of a company-wide rebranding initiative that will include content and new graphic elements related to the treatment of SUI in women. The rebranding is being completed in advance of the planned reporting of topline results from Viveve's pivotal U.S. |
Viveve to Participate in Ladenburg Thalmann Healthcare Conference/ Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that Scott Durbin, chief executive officer, will participate in the Ladenburg Thalmann Healthcare Conference, September 29, 2022, in New York City. Mr. Durbin will deliver the Viveve corporate presentation and provide an update on progress of the Company's SUI clinical development program. |
Viveve to Participate in Alliance Global Partners Virtual MedTech Conference/ Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that Scott Durbin, chief executive officer, will participate in the Alliance Global Partners Virtual MedTech Conference, September 21, 2022. |